Analysts’ Viewpoint on Market Scenario
Demand for non-invasive prenatal testing (NIPT) is increasing in several countries owing to the rise in number of doctors preferring advanced non-invasive DNA test for high-risk pregnancies, desire to delay pregnancy, and growth in pregnancy-related issues in the second or third trimester. The global market (NIPT) market is highly saturated, with the presence of a large number of players.
Companies are entering into partnerships and collaborations to maintain a stable position in the market. Improvements and advancements in existing products such as prenatal paternity testing and non-invasive prenatal paternity testing are driving the global market. Furthermore, countries such as the Netherlands are implementing policies to fully reimburse NIPT in the second trimester, which is resulting in higher adoption of these tests. Additionally, other countries such as Germany plan to reimburse non-invasive prenatal tests for chromosomal disorders such as Down’s syndrome.
Non-invasive prenatal testing (NIPT) is a novel genetic screening method based on the analysis of cell-free fetal DNA in the maternal plasma. NIPT screens for trisomy 21 (Down syndrome) as well as two other less common chromosome abnormalities: trisomy 13 and trisomy 18. Several companies are striving to create advanced screening methods that are sensitive and accurate in the early diagnosis of genetic abnormalities in infants.
Next-generation sequencing (NGS) is a commonly used technology for the identification of trisomy, micro-deletions, and aneuploidies in chromosomes. NGS-based noninvasive prenatal tests are different from other techniques, as they can be performed as early as 10 weeks of pregnancy. Additionally, other noninvasive prenatal tests offer about 96% accuracy, while NGS-based tests are more than 99% accurate.
The high incidence rate of babies born with Down’s syndrome and Turner’s syndrome across the globe is likely to drive the demand for non-invasive prenatal testing, primarily due to the high level of accuracy and safety offered over conventional screening and invasive diagnostic methods. The advantages of non-invasive prenatal tests, such as non-invasive nature, better accuracy, and short duration of the procedure, are anticipated to propel the global NIPT market during the forecast period.
According to sources from Down’s Syndrome Education (DSE) International, the prevalence of Down’s syndrome ranges from 1 in 1,500 to 1 in 400 babies born across different countries. Nearly 220,000 babies are born with Down’s syndrome globally every year. According to the CDC, the incidence rate stands at 1 in every 700 childbirths (around 6,000 annually) in the U.S. According to the Centers for Disease Control and Prevention (CDC), every year, around 6,000 babies born in the U.S suffer from Down’s syndrome, which is 1 in every 700 babies.
Globally, the average age of first-time mothers is increasing, especially in developed countries such as the U.S., the U.K., France, Germany, Italy, and Japan. Financial stability, rising literacy rates, and social factors are responsible for the advancing maternal age. The risk of fetal chromosomal abnormalities is directly related to the rise in maternal age.
According to the American Academy of Family Physicians (AAFP), the risk of fetal chromosomal abnormalities increases progressively up to the age of 30, then rapidly beyond that. According to sources, the chance of Down's syndrome in a newborn is 1/1,300 up to 25 years of maternal age, while the risk increases to 1/365 in pregnant women at 35 years of age and to 1/30 after 40 years. Thus, growth in average maternal age is likely to result in an increase in the incidence of chromosomal abnormalities, leading to a rise in demand for NIPTs.
In terms of test type, the global market has been classified into Materni21, Harmony, Panorama, Verifi, NIFTY, and others. The MaterniT21 segment accounted for a significant share of the global market in 2021. It is likely to be a highly lucrative segment during the forecast period. The MaterniT21 segment is anticipated to be driven by the strong brand reputation of Labcorp and the expected collaboration with local distributors in the near future.
In September 2019, Labcorp announced the findings of the largest research on cell-free DNA (cfDNA) screenings in multifetal pregnancies to date. The study, published in PLOS ONE (peer-reviewed open access scientific journal), concluded that non-invasive cfDNA screening with Labcorp's Integrated Genetics' MaterniT21 PLUS test delivered trustworthy findings that compared favorably to singleton pregnancies.
Based on application, the trisomy segment held a significant share of the global NIPT market in 2021. It is likely to be a highly lucrative segment during the forecast period. According to the United Nations, the estimated rate of incidence of Down’s syndrome ranges from 1 in 1,000 live births per year to 1 in 1,100 live births per year globally. Around 95% of cases of Down’s syndrome are nondisjunction cases, while translocation and mosaicism cases account for 5%.
The dominance of the trisomy segment can be ascribed to the rise in the prevalence of Down’s syndrome globally and the high efficiency of NIPT for screening of Down’s syndrome. Similarly, maternal age is the most important risk factor for trisomy. Women in their late 30s and 40s have a higher chance of having trisomy. Thus, a rise in average maternal age is anticipated to result in an increase in trisomy cases, which is likely to augment the segment.
In terms of technology, the next-generation sequencing (NGS) segment accounted for the largest global market share in 2021. NGS has gained significant popularity in NIPT. Furthermore, the majority of commercialized NIPT tests are based on next-generation sequencing technology. For instance, MaterniT21 and Harmony are based on the NGS technique.
Based on end-user, the diagnostic laboratories segment is anticipated to grow at a rapid pace during the forecast period due to improving diagnostic laboratory infrastructure as compared to hospitals. A large number of diagnostic laboratories across the globe offer NIPT. MedGenome Labs Ltd. offers MedGenome Claria NIPT test for the diagnosis of Trisomies 21, 18, and 13; Monosomy X; and other sex chromosomal abnormalities.
The company also offers Claria NIPT Plus, which is used to detect Down Syndrome, Edwards’ Syndrome, Patau Syndrome, Triploidy, Monosomy X (Turner Syndrome), Klinefelter Syndrome, Triple X, Jacob’s Syndrome, 22q11.2 Deletion Syndrome, 1p36 Deletion Syndrome, Prader-Willi Syndrome, Angelman Syndrome, and Cri-du-chat Syndrome.
North America dominated the global market, with more than 60% share in 2021, followed by Europe. A high rate of diagnosis and treatment of trisomy disorders, well-established healthcare infrastructure, and the presence of key companies in the U.S. are likely to drive the non-invasive prenatal testing market in North America during the forecast period.
The market in Asia Pacific is projected to grow at the fastest CAGR during the forecast period owing to the rise in maternal age, which contributes to the increase in the incidence of chromosomal aneuploidies in babies. Significant market developments in China and Japan, technological integration of NGS procedures, and improving healthcare infrastructure are the other factors propelling the market in the region.
The global market is consolidated due to the broad range of product offerings and strong distribution network of key players in emerging and developed countries. Companies have adopted several strategies, including partnership, merger, acquisition, and product expansion, to strengthen their market position. For instance, in June 2021, Next-Generation Genomic Co., Ltd., and Illumina, Inc. launched VeriSeq NIPT Solution v2 in Thailand.
VeriSeq NIPT Solution offers accurate, reliable, scalable, and fast end-to-end genome-wide noninvasive prenatal testing. Berry Genetics, BGI, Laboratory Corporation of America Holdings, Agilent Technologies, Inc., Illumina, Inc., F. Hoffmann-La Roche Ltd, Natera, Inc., PerkinElmer, Inc., Eurofins LifeCodexx AG, QIAGEN, Pacific Biosciences, and IGENOMIX are the key players operating in the global non-invasive prenatal testing industry.
Each of these players has been profiled in the non-invasive prenatal testing market report based on parameters such as company overview, financial overview, business strategies, product portfolio, business segments, and recent developments.
| Attribute | Detail |
|---|---|
| Market Size Value in 2021 | US$ 2.1 Bn |
| Market Forecast Value in 2031 | More than US$ 8.4 Bn |
| Growth Rate (CAGR) for 2022-2031 | 14.8% |
| Forecast Period | 2022-2031 |
| Historical Data Available for | 2017-2020 |
| Quantitative Units | US$ Bn for Value |
| Market Analysis | It includes segment analysis at the global as well as regional levels. Moreover, the qualitative analysis includes drivers, restraints, opportunities, key trends, and parent industry overview. |
| Competition Landscape |
|
| Format | Electronic (PDF) + Excel |
| Market Segmentation |
|
| Regions Covered |
|
| Countries Covered |
|
| Companies Profiled |
|
| Customization Scope | Available upon request |
| Pricing | Available upon request |
The global non-invasive prenatal testing industry was valued at US$ 2.1 Bn in 2021
The global market is projected to reach more than US$ 8.4 Bn by 2031
The global non-invasive prenatal testing market is anticipated to advance at a CAGR of 14.8% from 2022 to 2031
High incidence rate of Down’s syndrome
Berry Genetics, BGI, Laboratory Corporation of America Holdings, Agilent Technologies, Inc., Illumina, Inc., F. Hoffmann-La Roche Ltd., Natera, Inc., PerkinElmer, Inc., Eurofins LifeCodexx AG, QIAGEN, Pacific Biosciences, and IGENOMIX
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Non-invasive Prenatal Testing Market
4. Market Overview
4.1. Introduction
4.1.1. Test Type Definition
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Non-invasive Prenatal Testing Market Analysis and Forecast, 2017-2031
4.4.1. Market Revenue Projections (US$ Mn)
5. Key Insights
5.1. Key Industry Evolution/Developments
5.2. Cost Comparison Analysis
5.3. Advancement in NIPT
5.4. Covid 19 Impact Analysis
6. Global Non-invasive Prenatal Testing Market Analysis and Forecast, by Test Type
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Test Type, 2017-2031
6.3.1. Materni21
6.3.2. Harmony
6.3.3. Panorama
6.3.4. Verifi
6.3.5. NIFTY
6.3.6. Others
6.4. Market Attractiveness Analysis, by Test Type
7. Global Non-invasive Prenatal Testing Market Analysis and Forecast, by Application
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by Application, 2017-2031
7.3.1. Trisomy
7.3.2. Micro-deletions Symptoms
7.3.3. Others
7.4. Market Attractiveness Analysis, by Application
8. Global Non-invasive Prenatal Testing Market Analysis and Forecast, by Technology
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast, by Technology, 2017-2031
8.3.1. NGS
8.3.2. WGS
8.3.3. Others
8.4. Market Attractiveness Analysis, by Technology
9. Global Non-invasive Prenatal Testing Market Analysis and Forecast, by End-user
9.1. Introduction & Definition
9.2. Key Findings / Developments
9.3. Market Value Forecast, by End-user, 2017-2031
9.3.1. Hospitals
9.3.2. Diagnostic Laboratories
9.3.3. Others
9.4. Market Attractiveness Analysis, by End-user
10. Global Non-invasive Prenatal Testing Market Analysis and Forecast, by Region
10.1. Key Findings
10.2. Market Value Forecast, by Region
10.2.1. North America
10.2.2. Europe
10.2.3. Asia Pacific
10.2.4. Latin America
10.2.5. Middle East & Africa
10.3. Market Attractiveness Analysis, by Region
11. North America Non-invasive Prenatal Testing Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Test Type, 2017-2031
11.2.1. Materni21
11.2.2. Harmony
11.2.3. Panorama
11.2.4. Verifi
11.2.5. NIFTY
11.2.6. Others
11.3. Market Value Forecast, by Application, 2017-2031
11.3.1. Trisomy
11.3.2. Micro-deletions Symptoms
11.3.3. Others
11.4. Market Value Forecast, by Technology, 2017-2031
11.4.1. NGS
11.4.2. WGS
11.4.3. Others
11.5. Market Value Forecast, by End-user, 2017-2031
11.5.1. Hospitals
11.5.2. Diagnostic Laboratories
11.5.3. Others
11.6. Market Value Forecast, by Country, 2017-2031
11.6.1. U.S.
11.6.2. Canada
11.7. Market Attractiveness Analysis
11.7.1. By Test Type
11.7.2. By Application
11.7.3. By Technology
11.7.4. By End-user
11.7.5. By Country
12. Europe Non-invasive Prenatal Testing Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Test Type, 2017-2031
12.2.1. Materni21
12.2.2. Harmony
12.2.3. Panorama
12.2.4. Verifi
12.2.5. NIFTY
12.2.6. Others
12.3. Market Value Forecast, by Application, 2017-2031
12.3.1. Trisomy
12.3.2. Micro-deletions Symptoms
12.3.3. Others
12.4. Market Value Forecast, by Technology, 2017-2031
12.4.1. NGS
12.4.2. WGS
12.4.3. Others
12.5. Market Value Forecast, by End-user, 2017-2031
12.5.1. Hospitals
12.5.2. Diagnostic Laboratories
12.5.3. Others
12.6. Market Value Forecast, by Country/Sub-region, 2017-2031
12.6.1. Germany
12.6.2. U.K.
12.6.3. France
12.6.4. Spain
12.6.5. Italy
12.6.6. Rest of Europe
12.7. Market Attractiveness Analysis
12.7.1. By Test Type
12.7.2. By Application
12.7.3. By Technology
12.7.4. By End-user
12.7.5. By Country/Sub-region
13. Asia Pacific Non-invasive Prenatal Testing Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Test Type, 2017-2031
13.2.1. Materni21
13.2.2. Harmony
13.2.3. Panorama
13.2.4. Verifi
13.2.5. NIFTY
13.2.6. Others
13.3. Market Value Forecast, by Application, 2017-2031
13.3.1. Trisomy
13.3.2. Micro-deletions Symptoms
13.3.3. Others
13.4. Market Value Forecast, by Technology, 2017-2031
13.4.1. NGS
13.4.2. WGS
13.4.3. Others
13.5. Market Value Forecast, by End-user, 2017-2031
13.5.1. Hospitals
13.5.2. Diagnostic Laboratories
13.5.3. Others
13.6. Market Value Forecast, by Country/Sub-region, 2017-2031
13.6.1. China
13.6.2. Japan
13.6.3. India
13.6.4. Australia & New Zealand
13.6.5. Rest of Asia Pacific
13.7. Market Attractiveness Analysis
13.7.1. By Test Type
13.7.2. By Application
13.7.3. By Technology
13.7.4. By End-user
13.7.5. By Country/Sub-region
14. Latin America Non-invasive Prenatal Testing Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Test Type, 2017-2031
14.2.1. Materni21
14.2.2. Harmony
14.2.3. Panorama
14.2.4. Verifi
14.2.5. NIFTY
14.2.6. Others
14.3. Market Value Forecast, by Application, 2017-2031
14.3.1. Trisomy
14.3.2. Micro-deletions Symptoms
14.3.3. Others
14.4. Market Value Forecast, by Technology, 2017-2031
14.4.1. NGS
14.4.2. WGS
14.4.3. Others
14.5. Market Value Forecast, by End-user, 2017-2031
14.5.1. Hospitals
14.5.2. Diagnostic Laboratories
14.5.3. Others
14.6. Market Value Forecast, by Country/Sub-region, 2017-2031
14.6.1. Brazil
14.6.2. Mexico
14.6.3. Rest of Latin America
14.7. Market Attractiveness Analysis
14.7.1. By Test Type
14.7.2. By Application
14.7.3. By Technology
14.7.4. By End-user
14.7.5. By Country/Sub-region
15. Middle East & Africa Non-invasive Prenatal Testing Market Analysis and Forecast
15.1. Introduction
15.1.1. Key Findings
15.2. Market Value Forecast, by Test Type, 2017-2031
15.2.1. Materni21
15.2.2. Harmony
15.2.3. Panorama
15.2.4. Verifi
15.2.5. NIFTY
15.2.6. Others
15.3. Market Value Forecast, by Application, 2017-2031
15.3.1. Trisomy
15.3.2. Micro-deletions Symptoms
15.3.3. Others
15.4. Market Value Forecast, by Technology, 2017-2031
15.4.1. NGS
15.4.2. WGS
15.4.3. Others
15.5. Market Value Forecast, by End-user, 2017-2031
15.5.1. Hospitals
15.5.2. Diagnostic Laboratories
15.5.3. Others
15.6. Market Value Forecast, by Country/Sub-region, 2017-2031
15.6.1. GCC Countries
15.6.2. South Africa
15.6.3. Rest of Middle East & Africa
15.7. Market Attractiveness Analysis
15.7.1. By Test Type
15.7.2. By Application
15.7.3. By Technology
15.7.4. By End-user
15.7.5. By Country/Sub-region
16. Competition Landscape
16.1. Market Player - Competition Matrix (by tier and size of companies)
16.2. Market Share Analysis, by Company, 2021
16.3. Company Profiles
16.3.1. Berry Genetics
16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.1.2. Financial Analysis
16.3.1.3. Growth Strategies
16.3.1.4. SWOT Analysis
16.3.2. BGI
16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.2.2. Financial Analysis
16.3.2.3. Growth Strategies
16.3.2.4. SWOT Analysis
16.3.3. Laboratory Corporation of America Holdings
16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.3.2. Financial Analysis
16.3.3.3. Growth Strategies
16.3.3.4. SWOT Analysis
16.3.4. Agilent Technologies, Inc.
16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.4.2. Financial Analysis
16.3.4.3. Growth Strategies
16.3.4.4. SWOT Analysis
16.3.5. Illumina, Inc.
16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.5.2. Financial Analysis
16.3.5.3. Growth Strategies
16.3.5.4. SWOT Analysis
16.3.6. F. Hoffmann-La Roche Ltd.
16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.6.2. Financial Analysis
16.3.6.3. Growth Strategies
16.3.6.4. SWOT Analysis
16.3.7. PerkinElmer, Inc.
16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.7.2. Financial Analysis
16.3.7.3. Growth Strategies
16.3.7.4. SWOT Analysis
16.3.8. Eurofins LifeCodexx AG
16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.8.2. Financial Analysis
16.3.8.3. Growth Strategies
16.3.8.4. SWOT Analysis
16.3.9. QIAGEN
16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.9.2. Financial Analysis
16.3.9.3. Growth Strategies
16.3.9.4. SWOT Analysis
16.3.10. IGENOMIX
16.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.10.2. Financial Analysis
16.3.10.3. Growth Strategies
16.3.10.4. SWOT Analysis
16.3.11. Pacific Biosciences
16.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.11.2. Financial Analysis
16.3.11.3. Growth Strategies
16.3.11.4. SWOT Analysis
16.3.12. Natera, Inc.
16.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.12.2. Financial Analysis
16.3.12.3. Growth Strategies
16.3.12.4. SWOT Analysis
List of Tables
Table 01: Global Non-invasive Prenatal Testing Market Value Share, by Test Type, 2021
Table 02: Global Non-invasive Prenatal Testing Market Value Share, by Application, 2021
Table 03: Global Non-invasive Prenatal Testing Market Value (US$ Mn) Forecast, by Test Type, 2017-2031
Table 04: Global Non-invasive Prenatal Testing Market Value (US$ Mn) Forecast, by Application, 2017-2031
Table 05: Global Non-invasive Prenatal Testing Market Value (US$ Mn) Forecast, by Technology, 2017-2031
Table 06: Global Non-invasive Prenatal Testing Market Value (US$ Mn) Forecast, by End-user, 2017-2031
Table 07: Global Non-invasive Prenatal Testing Market Value (US$ Mn) Forecast, by Region, 2017-2031
Table 08: North America Non-invasive Prenatal Testing Market Value (US$ Mn) Forecast, by Test Type, 2017-2031
Table 09: North America Non-invasive Prenatal Testing Market Value (US$ Mn) Forecast, by Application, 2017-2031
Table 10: North America Non-invasive Prenatal Testing Market Value (US$ Mn) Forecast, by Technology, 2017-2031
Table 11: North America Non-invasive Prenatal Testing Market Value (US$ Mn) Forecast, by End-user, 2017-2031
Table 12: North America Non-invasive Prenatal Testing Market Value (US$ Mn) Forecast, by Country, 2017-2031
Table 13: Europe Non-invasive Prenatal Testing Market Value (US$ Mn) Forecast, by Test Type, 2017-2031
Table 14: Europe Non-invasive Prenatal Testing Market Value (US$ Mn) Forecast, by Application, 2017-2031
Table 15: Europe Non-invasive Prenatal Testing Market Value (US$ Mn) Forecast, by Technology, 2017-2031
Table 16: Europe Non-invasive Prenatal Testing Market Value (US$ Mn) Forecast, by End-user, 2017-2031
Table 17: Europe Non-invasive Prenatal Testing Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 18: Asia Pacific Non-invasive Prenatal Testing Market Value (US$ Mn) Forecast, by Test Type, 2017-2031
Table 19: Asia Pacific Non-invasive Prenatal Testing Market Value (US$ Mn) Forecast, by Application, 2017-2031
Table 20: Asia Pacific Non-invasive Prenatal Testing Market Value (US$ Mn) Forecast, by Technology, 2017-2031
Table 21: Asia Pacific Non-invasive Prenatal Testing Market Value (US$ Mn) Forecast, by End-user, 2017-2031
Table 22: Asia Pacific Non-invasive Prenatal Testing Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 23: Latin America Non-invasive Prenatal Testing Market Value (US$ Mn) Forecast, by Test Type, 2017-2031
Table 24: Latin America Non-invasive Prenatal Testing Market Value (US$ Mn) Forecast, by Application, 2017-2031
Table 25: Latin America Non-invasive Prenatal Testing Market Value (US$ Mn) Forecast, by Technology, 2017-2031
Table 26: Latin America Non-invasive Prenatal Testing Market Value (US$ Mn) Forecast, by End-user, 2017-2031
Table 27: Latin America Non-invasive Prenatal Testing Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 28: Middle East & Africa Non-invasive Prenatal Testing Market Value (US$ Mn) Forecast, by Test Type, 2017-2031
Table 29: Middle East & Africa Non-invasive Prenatal Testing Market Value (US$ Mn) Forecast, by Application, 2017-2031
Table 30: Middle East & Africa Non-invasive Prenatal Testing Market Value (US$ Mn) Forecast, by Technology, 2017-2031
Table 31: Middle East & Africa Non-invasive Prenatal Testing Market Value (US$ Mn) Forecast, by End-user, 2017-2031
Table 32: Middle East & Africa Non-invasive Prenatal Testing Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
List of Figures
Figure 01: Global Non-invasive Prenatal Testing Market Snapshot
Figure 02: Global Non-invasive Prenatal Testing Market Segments With Leading Market Share (%), 2021
Figure 03: Key Industry Developments (Non-invasive Prenatal Testing Market)
Figure 04: Global Non-invasive Prenatal Testing Market Value (US$ Mn) Forecast, 2017-2031
Figure 05: Global Non-invasive Prenatal Testing Market Value Share (%), by Test Type (2021)
Figure 06: Global Non-invasive Prenatal Testing Market Value Share (%), by Application (2021)
Figure 07: Global Non-invasive Prenatal Testing Market Value Share (%), by Technology (2021)
Figure 08: Global Non-invasive Prenatal Testing Market Value Share(%), by End-user (2021)
Figure 09: Global Non-invasive Prenatal Testing Market Value Share (%), by Region (2021)
Figure 10: Global Non-invasive Prenatal Testing Market Value Share Analysis, by Test Type, 2021 and 2031
Figure 11: Global Non-invasive Prenatal Testing Market Attractiveness Analysis, by Test Type, 2022-2031
Figure 12: Global Non-invasive Prenatal Testing Market Value Share Analysis, by Application, 2021 and 2031
Figure 13: Global Non-invasive Prenatal Testing Market Attractiveness Analysis, by Application, 2022-2031
Figure 14: Global Non-invasive Prenatal Testing Market Value Share Analysis, by Technology, 2021 and 2031
Figure 15: Global Non-invasive Prenatal Testing Market Attractiveness Analysis, by Technology, 2022-2031
Figure 16: Global Non-invasive Prenatal Testing Market Value Share(%), by End-user, 2021 and 2031
Figure 17: Global Non-invasive Prenatal Testing Market Attractiveness Analysis, by End-user, 2022-2031
Figure 18: Global Non-invasive Prenatal Testing Market Value Share Analysis, by Region 2021 and 2031
Figure 19: Global Non-invasive Prenatal Testing Market Attractiveness Analysis, by Region, 2022-2031
Figure 20: North America Non-invasive Prenatal Testing Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017-2031
Figure 21: North America Non-invasive Prenatal Testing Market Value Share (%), by Test Type, 2021 and 2031
Figure 22: North America Non-invasive Prenatal Testing Market Attractiveness Analysis, by Test Type, 2022-2031
Figure 23: North America Non-invasive Prenatal Testing Market Value Share (%), by Application, 2021 and 2031
Figure 24: North America Non-invasive Prenatal Testing Market Attractiveness Analysis, by Application, 2022-2031
Figure 25: North America Non-invasive Prenatal Testing Market Value Share (%), by Technology, 2021 and 2031
Figure 26: North America Non-invasive Prenatal Testing Market Attractiveness Analysis, by Technology, 2022-2031
Figure 27: North America Non-invasive Prenatal Testing Market Share (%), by End-user, 2021 and 2031
Figure 28: North America Non-invasive Prenatal Testing Market Attractiveness Analysis, by End-user, 2022-2031
Figure 29: North America Non-invasive Prenatal Testing Market Value Share (%), by Country, 2021 and 2031
Figure 30: North America Non-invasive Prenatal Testing Market Attractiveness Analysis, by Country, 2022-2031
Figure 31: Europe Non-invasive Prenatal Testing Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017-2031
Figure 32: Europe Non-invasive Prenatal Testing Market Value Share (%), by Test Type, 2021 and 2031
Figure 33: Europe Non-invasive Prenatal Testing Market Attractiveness Analysis, by Test Type, 2022-2031
Figure 34: Europe Non-invasive Prenatal Testing Market Value Share (%), by Application, 2021 and 2031
Figure 35: Europe Non-invasive Prenatal Testing Market Attractiveness Analysis, by Application, 2022-2031
Figure 36: Europe Non-invasive Prenatal Testing Market Value Share (%), by Technology, 2021 and 2031
Figure 37: Europe Non-invasive Prenatal Testing Market Attractiveness Analysis, by Technology, 2022-2031
Figure 38: Europe Non-invasive Prenatal Testing Market Share (%), by End-user, 2021 and 2031
Figure 39: Europe Non-invasive Prenatal Testing Market Attractiveness Analysis, by End-user, 2022-2031
Figure 40: Europe Non-invasive Prenatal Testing Market Value Share (%), by Country/Sub-region, 2021 and 2031
Figure 41: Europe Non-invasive Prenatal Testing Market Attractiveness Analysis, by Country/Sub-region, 2022-2031
Figure 42: Asia Pacific Non-invasive Prenatal Testing Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017-2031
Figure 43: Asia Pacific Non-invasive Prenatal Testing Market Value Share (%), by Test Type, 2021 and 2031
Figure 44: Asia Pacific Non-invasive Prenatal Testing Market Attractiveness Analysis, by Test Type, 2022-2031
Figure 45: Asia Pacific Non-invasive Prenatal Testing Market Value Share (%), by Application, 2021 and 2031
Figure 46: Asia Pacific Non-invasive Prenatal Testing Market Attractiveness Analysis, by Application, 2022-2031
Figure 47: Asia Pacific Non-invasive Prenatal Testing Market Value Share (%), by Technology, 2021 and 2031
Figure 48: Asia Pacific Non-invasive Prenatal Testing Market Attractiveness Analysis, by Technology, 2022-2031
Figure 49: Asia Pacific Non-invasive Prenatal Testing Market Share (%), by End-user, 2021 and 2031
Figure 50: Asia Pacific Non-invasive Prenatal Testing Market Attractiveness Analysis, by End-user, 2022-2031
Figure 51: Asia Pacific Non-invasive Prenatal Testing Market Attractiveness Analysis, by End-user, 2021 and 2031
Figure 52: Asia Pacific Non-invasive Prenatal Testing Market Attractiveness Analysis, by Country/Sub-region, 2022-2031
Figure 53: Latin America Non-invasive Prenatal Testing Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017-2031
Figure 54: Latin America Non-invasive Prenatal Testing Market Value Share (%), by Test Type, 2021 and 2031
Figure 55: Latin America Non-invasive Prenatal Testing Market Attractiveness Analysis, by Test Type, 2022-2031
Figure 56: Latin America Non-invasive Prenatal Testing Market Value Share (%), by Application, 2021 and 2031
Figure 57: Latin America Non-invasive Prenatal Testing Market Attractiveness Analysis, by Application, 2022-2031
Figure 58: Latin America Non-invasive Prenatal Testing Market Value Share (%), by Technology, 2021 and 2031
Figure 59: Latin America Non-invasive Prenatal Testing Market Attractiveness Analysis, by Technology, 2022-2031
Figure 60: Latin America Non-invasive Prenatal Testing Market Share (%), by End-user, 2021 and 2031
Figure 61: Latin America Non-invasive Prenatal Testing Market Attractiveness Analysis, by End-user, 2022-2031
Figure 62: Latin America Non-invasive Prenatal Testing Market Value Share (%), by Country/Sub-region, 2021 and 2031
Figure 63: Latin America Non-invasive Prenatal Testing Market Attractiveness Analysis, by Country/Sub-region, 2022-2031
Figure 64: Middle East & Africa Non-invasive Prenatal Testing Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017-2031
Figure 65: Middle East & Africa Non-invasive Prenatal Testing Market Value Share (%), by Test Type, 2021 and 2031
Figure 66: Middle East & Africa Non-invasive Prenatal Testing Market Attractiveness Analysis, by Test Type, 2022-2031
Figure 67: Middle East & Africa Non-invasive Prenatal Testing Market Value Share (%), by Application, 2021 and 2031
Figure 68: Middle East & Africa Non-invasive Prenatal Testing Market Attractiveness Analysis, by Application, 2022-2031
Figure 69: Middle East & Africa Non-invasive Prenatal Testing Market Value Share (%), by Technology, 2021 and 2031
Figure 70: Middle East & Africa Non-invasive Prenatal Testing Market Attractiveness Analysis, by Technology, 2022-2031
Figure 71: Middle East & Africa Non-invasive Prenatal Testing Market Share (%), by End-user, 2021 and 2031
Figure 72: Middle East & Africa Non-invasive Prenatal Testing Market Attractiveness Analysis, by End-user, 2022-2031
Figure 73: Middle East & Africa Non-invasive Prenatal Testing Market Value Share (%), by Country/Sub-region, 2021 and 2031
Figure 74: Middle East & Africa Non-invasive Prenatal Testing Market Attractiveness Analysis, by Country/Sub-region, 2022-2031
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Non-invasive Prenatal Testing Market
